A real-world study: third-line treatment options for metastatic colorectal cancer

A real-world study: third-line treatment options for metastatic colorectal cancer

BackgroundNumerous third-line treatment options exist for colorectal cancer. This study aims to assess the efficacy and safety of third-line therapies, including TKIs (fruquintinib, regorafenib) combined with PD-1 inhibitors, and trifluridine/tipiracil combined with bevacizumab, in patients with ref...

Full description

Saved in:

Bibliographic Details
Main Authors:	Chen Wu, Shuai Li, Xinfang Hou
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2024-12-01
Series:	Frontiers in Oncology
Subjects:	colorectal cancer targeted therapies PD-1 inhibitors bevacizumab oncology
Online Access:	https://www.frontiersin.org/articles/10.3389/fonc.2024.1480704/full
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Trifluridine/tipiracil regimen in combination with bevacizumab for metastatic colorectal cancer in the third line: an expert opinion
by: Carmine Pinto, et al.
Published: (2025-01-01)

Bevacizumab for the treatment of metastatic colorectal cancer complicated by abdominal aortic aneurysm and mural thrombus: a case report
by: Yujun Li, et al.
Published: (2024-11-01)

Cost-effectiveness analysis of trifluridine/tipiracil combined with bevacizumab vs. monotherapy for third-line treatment of colorectal cancer
by: Long-Zhuan Huang, et al.
Published: (2024-11-01)

Efficacy and safety of anlotinib combined with immune checkpoint inhibitors and platinum-containing chemotherapy for later-line advanced non-small cell lung cancer: a retrospective three-arm real-world study using propensity-score matching
by: Zeyang Wang, et al.
Published: (2024-11-01)

EGFR inhibitors in the treatment of colorectal cancer
by: M. В. Zabelin, et al.
Published: (2018-09-01)

PD-L1 positive platelets mediate resistance to immune checkpoint inhibitors in patients with colorectal cancer
by: Jiacheng Li, et al.
Published: (2025-01-01)

Second‐line treatment options in advanced thymic carcinoma after failure of platinum‐based chemotherapy: A multicenter retrospective study
by: Yang Wang, et al.
Published: (2023-02-01)

Fusobacterium nucleatum upregulates the immune inhibitory receptor PD-L1 in colorectal cancer cells via the activation of ALPK1
by: Coco Duizer, et al.
Published: (2025-12-01)

Immune Checkpoint Blockade Combined with AbnobaViscum<sup>®</sup> Therapy Is Linked to Improved Survival in Advanced or Metastatic Non-Small-Cell Lung Cancer Patients: A Registry Study in Accordance with the ESMO Guidance for Reporting Real-World Evidence
by: Friedemann Schad, et al.
Published: (2024-12-01)

Correspondence to editorial on “Sorafenib vs. Lenvatinib in advanced hepatocellular carcinoma after atezolizumab/bevacizumab failure: A real-world study”
by: Young Eun Chon, et al.
Published: (2024-10-01)

Progression patterns in patients with advanced hepatocellular carcinoma treated with local therapy, targeted drugs, and PD-1/PD-L1 inhibitors
by: Yanan Zhao, et al.
Published: (2024-08-01)

Cellular mechanisms of combining innate immunity activation with PD-1/PD-L1 blockade in treatment of colorectal cancer
by: Qi Xie, et al.
Published: (2024-11-01)

Survival Outcomes with Regorafenib and/or Trifluridine/Tipiracil Sequencing to Rechallenge with Third-Line Regimens in Metastatic Colorectal Cancer: A Multicenter Retrospective Real-World Subgroup Comparison from the ReTrITA Study
by: Carlo Signorelli, et al.
Published: (2024-12-01)

Renal impairment as a risk factor for chemotherapy induced neutropenia in the treatment of trifluridine/thymidine phosphorylase inhibitor plus bevacizumab
by: Masatsune Shibutani, et al.
Published: (2025-01-01)

Atezolizumab plus bevacizumab in patients with unresectable or metastatic mucosal melanoma: 3‐year survival update and multi‐omics analysis
by: Jie Dai, et al.
Published: (2025-01-01)

Second-line treatment patterns and outcomes in advanced HCC after progression on atezolizumab/bevacizumab
by: Meng Wu, et al.
Published: (2025-02-01)

Chang-Wei-Qing Combined with PD-1 Inhibitor Alleviates Colitis-Associated Colorectal Tumorigenesis by Modulating the Gut Microbiota and Restoring Intestinal Barrier
by: Junkai Wen, et al.
Published: (2024-12-01)

Immune-related adverse events with PD-1/PD-L1 inhibitors: insights from a real-world cohort of 2523 patients
by: Ting Yan, et al.
Published: (2025-01-01)

Inhibition of DDR1‐BCR signalling by nilotinib as a new therapeutic strategy for metastatic colorectal cancer
by: Maya Jeitany, et al.
Published: (2018-02-01)

The Potential of PD-1 and PD-L1 as Prognostic and Predictive Biomarkers in Colorectal Adenocarcinoma Based on TILs Grading
by: Nur Rahmah Rasyid, et al.
Published: (2024-11-01)

Efficacy and safety of first-line immunotherapy-containing regimens compared with chemotherapy for advanced or metastatic urothelial carcinoma: a network meta-analysis of randomized controlled trials
by: Weiming Liang, et al.
Published: (2024-12-01)

Efficacy and safety of PD-1 and PD-L1 inhibitors in advanced colorectal cancer: a meta-analysis of randomized controlled trials
by: Zhenzi Wang, et al.
Published: (2024-12-01)

Transarterial therapy combined with bevacizumab plus immune checkpoint inhibitors as a neoadjuvant therapy for locally advanced HCC
by: Zhenyun Yang, et al.
Published: (2024-12-01)

TAS-102 Plus Bevacizumab as an Effective and Well Tolerated Regimen in Chemotherapy-Refractory Advanced Colorectal Cancers – A Single Institution Retrospective Analysis
by: Ritam Joarder, et al.

Immune-checkpoint-inhibitor therapy directed against PD-L1 is tolerated in the heart without manifestation of cardiac inflammation in a preclinical reversible melanoma mouse model
by: Caroline Schoenherr, et al.
Published: (2025-01-01)

Atezolizumab and bevacizumab for hepatocellular carcinoma: How to approach salvage therapy for non-responders?: Editorial on “Sorafenib vs. Lenvatinib in advanced hepatocellular carcinoma after atezolizumab/bevacizumab failure: A real-world study”
by: Naoshi Nishida
Published: (2024-10-01)

Polo-like Kinase 1 Expression as a Biomarker in Colorectal Cancer: A Retrospective Two-Center Study
by: Lana Jajac Brucic, et al.
Published: (2024-12-01)

Current advances in immunotherapy for cancer
by: Indrajit Desai, et al.
Published: (2024-12-01)

The efficacy and safety of neoadjuvant treatment with the PD-1 inhibitor for locally advanced colorectal cancer: a meta-analysis
by: Yan Yu, et al.
Published: (2024-12-01)

Colorectal cancer spectrum: From subtypes and epidemiology to oncotherapies
by: Nidhi Agrawal, et al.
Published: (2025-04-01)

The real-world efficacy and toxicity of first-line paclitaxel and cisplatin with bevacizumab in platinum-naïve primary stage IVB cervical cancer
by: Junhwan Kim, et al.
Published: (2025-01-01)

MODERN TREATMENT OF METASTATIC MELANOMA: FROM STANDARDS TO AN INDIVIDUALIZED APPROACH IN REAL CLINICAL PRACTICE
by: N. V. Zhukova, et al.
Published: (2018-06-01)

Efficacy and safety of PD-1/PD-L1 inhibitors in advanced or recurrent endometrial cancer: a meta-analysis with trial sequential analysis of randomized controlled trials
by: Ji Ren, et al.
Published: (2025-01-01)

COMPARATIVE EVALUATION OF THE USE OF COATED AND UNCOATED SELF-EXPANDABLE METALLIC STENTS IN MALIGNANT COLORECTAL OBSTRUCTION
by: V. A. Duvanskiy, et al.
Published: (2020-03-01)

Inhibition or promotion, the potential role of arginine metabolism in immunotherapy for colorectal cancer
by: Chengyang Chen, et al.
Published: (2023-12-01)

Isobutyric Acid Promotes Immune Evasion in Colorectal Cancer via Increased PD‐L1 Expression
by: Qiuhua Lin, et al.
Published: (2024-11-01)

Targeting cuproptosis with nano material: new way to enhancing the efficacy of immunotherapy in colorectal cancer
by: Xiangdong Liu, et al.
Published: (2024-12-01)

Checkpoint based immunotherapy in non-small cell lung cancer: a real-world retrospective study
by: Luigi Liguori, et al.
Published: (2024-11-01)

FXR agonist GW4064 enhances anti-PD-L1 immunotherapy in colorectal cancer
by: Lu Lu, et al.
Published: (2023-12-01)

Impact of renal impairment on early development of severe neutropenia with trifluridine/tipiracil treatment for metastatic colorectal cancer
by: Yoshitaka Saito, et al.
Published: (2024-11-01)